Trump orders overhaul of kidney disease payments and treatment

White House
Trump said the government hopes to save about $4.2 billion in overall treatment costs, by moving patients to kidney transplants sooner versus having them on prolonged dialysis. (Andrew Soundarajan / iStock / Getty Images)

The Trump administration has put forward an executive order designed to incentivize at-home kidney dialysis, potentially affecting tens of thousands of people who undergo the procedure at commercial clinics.

The order also aims to create new payment models for transplants, and hopes to encourage the development of artificial organs—with the goal of doubling the total number of available kidneys by 2030. Currently, more than 100,000 people are waiting for a potential kidney transplant.

Shares of DaVita and Fresenius Medicare Care, two of the largest operators of dialysis centers in the U.S., both took hits earlier this week after Politico broke the news ahead of the White House’s official announcement Wednesday morning. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

There, President Donald Trump said the order would direct the government to reimburse kidney donors for additional costs associated with the procedure—such as for lost wages and child care expenses—and would change the structure of Medicare reimbursements for at-home dialysis care. 

RELATED: CVS develops medical device to corner home dialysis market

Trump also said the government hopes to save about $4.2 billion in overall treatment costs, by moving patients to kidney transplants sooner compared to having them on prolonged dialysis.

In a statement, DaVita said it was “energized” by the administration’s focus on combating kidney disease, which Trump described as a core national priority in his announcement. 

"We've been investing in capabilities to deliver holistic care that addresses our patients' needs beyond kidney disease, such as mental health, social services and nutrition,” said DaVita CEO Javier Rodriguez. “We will continue to work with the administration and Congress to launch programs that address broader care opportunities."

According to the Centers for Disease Control and Prevention, nearly 125,000 people in the U.S. began treatments for end-stage kidney disease in 2016, with more than 726,000 being on dialysis or living with a kidney transplant.

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Elon Musk pulled back the curtain on his brain interface-developing Neuralink, saying the startup holds the promise of merging people with AI.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.